This is a study in chronic stable Schizophrenia with the purpose to answer the question of
whether agonism of the nicotinic alpha7 receptor is capable of enhancing cognition in a well
defined chronic stable patient population treated with antipsychotics as standard of care,
and thus to support the future development of AQW051 for the treatment of cognitive
impairment associated with Schizophrenia (CIAS).